VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported positive results from a bias analysis conducted for its concluded Phase 3 study of Multikine (Leukocyte ...

Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...

SELLAS Life Science announced that the pre-specified threshold of 60 events has been reached in its ongoing Phase 3 REGAL clinical trial of galinpepimut-S, GPS, in acute myeloid leukemia, AML, ...

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not applicable; NGS, next-generation sequencing; PCR, polymerase chain reaction. Fig 1. Kaplan-Meier estimates of (A) ...

Phase shift analysis remains a cornerstone of modern scattering theory, underpinning our understanding of how particles interact under various potential fields. By examining the phase differences ...

A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713). The broad-spectrum KIT inhibitor NB003 and activity in ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

The clinical database has been finalized for the pre-specified interim efficacy analysis in Diamyd Medical's ongoing pivotal Phase 3 trial (DIAGNODE-3) evaluating retogatein (rhGAD65) in individuals w ...

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...